Clinical Trials Directory

Trials / Completed

CompletedNCT01367561

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

A Phase I Urodynamic Study of the Opioid Antagonist, Naloxone and Intravenous Methylnaltrexone Reverse Opioid Effects on Bladder Function in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Bausch Health Americas, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.

Conditions

Interventions

TypeNameDescription
DRUGNaloxone
DRUGIV Methylnaltrexone (MNTX)
DRUGPlacebo

Timeline

Start date
2002-10-01
Primary completion
2003-05-01
Completion
2003-05-01
First posted
2011-06-07
Last updated
2023-04-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01367561. Inclusion in this directory is not an endorsement.

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function (NCT01367561) · Clinical Trials Directory